106th Annual General Meeting of Shareholders

About the 106th Annual General Meeting

Santen Pharmaceutical Co., Ltd. held its 106th Annual General Meeting of Shareholders for the fiscal year 2017 on June 26, 2018. The Meeting started at 10:00 a.m. and ended at 11:31 a.m. The number of shareholders attended was 701.

Matters reported
  1. Business Report, Consolidated Financial Statements and Non-consolidated Financial Statements for the 106th Business Term (April 1, 2017 to March 31, 2018)
  2. Independent Auditors Report and Corporate Auditors Report on the consolidated Financial Statements for the 106th Business Term (April 1, 2017 to March 31, 2018)
Questions We received questions regarding the following subjects from 7 shareholders and responded in kind.
  • Appointment of foreign directors.
  • Concurrent situation of outside directors.
  • Plan of future share repurchase.
  • Reason for ROE to be decreased in FY 2018.
  • Reason for shareholders decrease.
  • Oversea expansion of OTC products.
  • Measures for global expansion
  • Specific numerical target of MTP2020.
  • Measures to increase individual shareholders.
  • MicroShunt's potential in Japanese market and sales scale.
  • Period of time for doctors acquiring surgical skill of MicroShunt.
  • Sales scale and launch timing of DE-109
  • Dividend policy.
Matters resolved Four proposals were all resolved.
Please refer to the Resolution Notice (PDF: 25KB)PDF for detailed resolutions.